2 Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States[J]. Drugs, 2003, 63(24): 2769-2802.
12 Nista E, Candelli M. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication: update[J]. Gastroenterology, 2005, 101(9):1985-1989
[13]
13 Bilardi C, Dulbecco P, Zentilin PA, et al. A 10-Day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial[J]. Clin Gastroenterol Hepatol, 2004, 2(11): 997-1002.
[14]
14 Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial[J]. Aliment Pharmacol Ther, 2003, 18(6): 627-633.
[15]
15 Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection[J]. Aliment Pharmacol Ther, 2003, 17(4): 553-560.
[16]
16 Moon JY, Kim GH, You HS, et al. Levofloxacin, metronidazole, and lansoprazole triple therapy compared to quadruple therapy as a second-line treatment of Helicobacter pylori infection in Korea[J]. Gut Liver, 2013, 7(4): 406-410.
[17]
17 Xia H, Wong B, Lam SK. Helicobacter pylori infection and gastric cancer[J]. Asian J Surg, 2001, 24(3): 217-222.
[18]
18 Wong, Shiu KL, Wai M, et al. Helicobacter pylori eradication to prevent gastric cancer in a high region of China[J]. JAMA, 2004, 291(2): 187-194.
